Lynk Pharmaceuticals Completes Enrollment for Ankylosing Spondylitis Trial

The randomized, double-blind study evaluates the efficacy and safety of the drug, with a primary endpoint focused on patients achieving an ASAS40 response by the 16th week. Zemprocitinib, a second-generation selective JAK1 inhibitor, is designed to minimize the off-target effects often seen in earlier iterations of the class. Previous data from rheumatoid arthritis and atopic dermatitis trials suggest the medication offers both rapid efficacy and a favorable safety profile compared to placebos.

Dr. Zhao-Kui Wan, founder and CEO of Lynk Pharmaceuticals, noted that this milestone serves to validate the clinical value of the therapy for a condition that frequently leads to severe spinal stiffness and impaired physical function. The company, which maintains a research focus on the JAK-STAT signaling pathway, plans to use the data gathered from these 352 patients to support forthcoming regulatory filings. As the study progresses through treatment and follow-up phases, the firm remains committed to expanding its pipeline of small-molecule therapies intended to replace more invasive biologic treatments.